🇺🇸 FDA
Patent

US 9283238

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/675A61K9/0053

Quick answer

US patent 9283238 (Prodrugs of 2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/675, A61K9/0053, A61P, A61P1/04